Genus plc stock - gnsuk news, historical stock charts, analyst ratings, financials, and today’s genus plc stock price net money flow is the value of uptick . Pic adding value in pig genetics abs adding value in bovine genetics world class animal genetics adding value for shareholders pic and abs are brand names of genus plc and registered trade marks. Genus plc is a breed apart it ranks as the largest animal-genetics company in the world it conducts research and development in the fields of genetics and .
Genus breeding india (abs india) is part of genus plc – the world’s leading provider of bovine genetics and reproduction services, marketing in nearly 80 countries around the globe. Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk the company's segments include genus pic, genus abs, genus asia, and research and development. The latest genus plc (gns) ordinary 10p share price (gns) if you decide to invest, read our important investment notes first and remember that investments can go up and down in value, . Request genus plc information our strategic framework about us our strategic framework we do this by demonstrating the value of our genetics through trials .
Genus plc has a book value per share: £676 (lse:gns) genus plc book value per share description, competitive comparison data, historical data and more. Genus plc has a peter lynch fair value: n/a (lse:gns) genus plc peter lynch fair value description, competitive comparison data, historical data and more. Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk.
Find out all the key statistics for genus plc ord 10p (gnsl), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Genus plc is a british-based business selling products manufactured using biotechnology to cattle and pig farmers it is headquartered in basingstoke and is a constituent of the ftse 250 index contents. Genus plc interim results for the six months ended 31 december 2013 continued strategic progress genus plc (the company or the group), a leading animal genetics company, announces its results for the six months ended 31 december 2013.
Genus plc (lon:gns) insider karim bitar sold 5,920 shares of the stock in a transaction that occurred on monday, september 17th the stock was sold at an average price of gbx 2,538 ($3306), for a total value of £150,24960 ($195,71395). Genus plc is a united kingdom-based company engaged in the development and marketing of biotechnology and value added products for the improvement of animal breeding the company provides natural animal genetics aiming for the bovine and porcine supply chain. Details for genus plc - dealing minimum size gbp 1 margin factor 200% minimum the value of shares, etfs and etcs bought through a share dealing account, a stocks .
Genus plc shares outstanding analysis of genus plc shares outstanding, outstanding shares that are stated on company balance sheet are used when calculating many important valuation and performance indicators including return on equity, market cap, eps and many others. Latest share prices for genus (gns) including charting, last trade, news, history and share dealing online, buy and sell genus shares.
Ratios valuation of genus plc ( gns | gbr) the ev/ebitda ntm ratio (also called ebitda multiple or enterprise multiple) is a well-known company valuation metric that compares a company's overall value to its operational earning power. Name description robert lawson: mr robert a lawson, (bob) serves as non-executive independent chairman of the board of genus plc he has significant experience of leading international . Updated key statistics for genus plc - including gns margins, p/e ratio, valuation, profitability, company description, and other stock analysis data. Genus plc ord 10p genus is listed in the ftse 250 , ftse all-share , ftse 350 , ftse 350 low yield genus is part of the medicine and biotech research sector.